A Phase 2 interventional study of tofacitinib ointment 20 mg/g and tofacitinib ointment 10 mg/g in Psoriasis Vulgaris and Psoriasis, sponsored by Pfizer. Completed at 54 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-11-25.
Sponsored by Pfizer · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing tofacitinib in Psoriasis — 4 open to participants now, 4 under way, 1 of them phase 3. tofacitinib · Psoriasis.
Among the 19 studies testing tofacitinib in Psoriasis, this one is the 7th largest by enrollment, is one of 3 that started in 2013, is one of 6 in phase 2, and was the 13th registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →4 of the 19 studies testing tofacitinib in Psoriasis are open now, in 3 countries. Recruiting first, the newest first:
Lahore General Hospital · Sites in Pakistan
Ages 18–70 · Healthy volunteers
University of California, San Francisco · Sites in United States
Ages 18+
Second Affiliated Hospital, Zhejiang University, School of Medicine · Sites in China
Ages 18+
Pak Emirates Military Hospital
Ages 18–70
By country, each count listing its studies:
tofacitinib: first FDA approval 2012 (XELJANZ), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 3 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 476 is above the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 135 across the 19 interventional studies. Of the 15 that completed or were terminated, 15 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 19 have an industry lead sponsor. The 6 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
57 studies in Psoriasis by Pfizer: none open now, none under way, none of them phase 3. Of 56 finished, 46 (82%) have results posted.
Among the 57 studies in Psoriasis by Pfizer, this one is the 10th largest by enrollment of the 42 interventional ones that give a count, is one of 4 that started in 2013, is one of 13 in phase 2, and was the 44th registered.
Pfizer’s Psoriasis studies by the year they started, since 2002.
1 of the studies testing tofacitinib in Psoriasis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07581418Pak Emirates Military HospitalComparison of Methotrexate and Tofacitinib in Chronic Plaque Psoriasis | 2026-12-01 |
Add it to your calendar (.ics) → With an account.
Among the 19 studies testing tofacitinib in Psoriasis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Pfizer’s 57 in Psoriasis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The study is beng done to test if tofacitinib ointment is safe and effective for people with plaque psoriasis. Two dose strengths of tofacitinib ointment (20 mg/g and 10 mg/g) applied once or twice daily are being tested. The safety and effectiveness of tofacitinib ointment used for 12 weeks will be compared to the safety and effectiveness of placebo ointment (vehicle) used for 12 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: tofacitinib ointment 20 mg/g
Drug: tofacitinib ointment 10 mg/g
Drug: placebo ointment (vehicle)
Drug: tofacitinib ointment 20 mg/g
Drug: tofacitinib ointment 10 mg/g
Drug: placebo ointment (vehicle)
Drug page: Tofacitinib
tofacitinib ointment 20 mg/g BID (twice daily) for 12 weeks
Drug page: Tofacitinib
tofacitinib ointment 10 mg/g BID (twice daily) for 12 weeks
placebo ointment (vehicle) BID (twice daily) for 12 weeks
Drug page: Tofacitinib
tofacitinib ointment 20 mg/g QD (once daily) for 12 weeks
Drug page: Tofacitinib
tofacitinib ointment 10 mg/g QD (once daily) for 12 weeks
placebo ointment (vehicle) QD (once daily) for 12 weeks
Percentage of Participants Achieving a PGA-C Response of Clear (0) or Almost Clear (1) and Greater Than or Equal to (≥) 2 Grade/Point Improvement From Baseline at Week 12
Clinical signs of plaque psoriasis (erythema \[E\], induration \[I\], and scaling \[S\]) were scored separately according to a 5-point severity scale (0 to 4) to provide PGA subscores, which described the overall severity of each clinical sign. The PGA-C was a static assessment; i.e., without regard to a previous assessment. The PGA subscores are then summed and averaged after which the total average was rounded to the nearest whole number to determine the PGA-C score and category. A higher score indicated a higher level of severity. 0 is equal to (=) cleared except for any residual discoloration and 1=almost clear, majority of lesions had individual scores for E+I+S that when summed, averaged, and rounded equaled 1.
Time frame: Baseline, Week 12
Percentage of Participants Achieving a PGA-C Response of Clear (0) or Almost Clear (1) and ≥2 Grade/Point Improvement From Baseline at Week 8
Clinical signs of plaque psoriasis (E, I, and S) were scored separately according to a 5-point severity scale (0 to 4) to provide PGA subscores, which described the overall severity of each clinical sign. The PGA-C was a static assessment; i.e., without regard to a previous assessment. The PGA subscores are then summed and averaged after which the total average was rounded to the nearest whole number to determine the PGA-C score and category. A higher score indicated a higher level of severity. 0 is equal to (=) cleared except for any residual discoloration and 1=almost clear, majority of lesions had individual scores for E+I+S that when summed, averaged, and rounded equaled 1.
Time frame: Baseline, Week 8
Percentage of Participants Achieving a PGA-C Response of Clear (0) or Almost Clear (1) at Week 12
Clinical signs of plaque psoriasis (E, I, and S) were scored separately according to a 5-point severity scale (0 to 4) to provide PGA subscores, which described the overall severity of each clinical sign. The PGA-C was a static assessment; i.e., without regard to a previous assessment. The PGA subscores are then summed and averaged after which the total average was rounded to the nearest whole number to determine the PGA-C score and category. A higher score indicated a higher level of severity. 0 is equal to (=) cleared except for any residual discoloration and 1=almost clear, majority of lesions had individual scores for E+I+S that when summed, averaged, and rounded equaled 1.
Time frame: Week 12
Percentage of Participants Achieving a PGA-C Response of Clear (0) or Almost Clear (1) at Week 8
Clinical signs of plaque psoriasis (E, I, and S) were scored separately according to a 5-point severity scale (0 to 4) to provide PGA subscores, which described the overall severity of each clinical sign. The PGA-C was a static assessment; i.e., without regard to a previous assessment. The PGA subscores are then summed and averaged after which the total average was rounded to the nearest whole number to determine the PGA-C score and category. A higher score indicated a higher level of severity. 0 is equal to (=) cleared except for any residual discoloration and 1=almost clear, majority of lesions had individual scores for E+I+S that when summed, averaged, and rounded equaled 1.
Time frame: Week 8
Percentage of Participants Achieving a Gestalt Physician's Global Assessment (PGA-G) Response of Clear (0) or Almost Clear (1) and ≥2 Grade/Point Improvement From Baseline at Week 12
Clinical signs of plaque psoriasis (E, I and S) were scored separately according to a 5-point severity scale (0 to 4) to provide PGA subscores, which described the overall severity of each clinical sign. After scoring each of the PGA subscores, a clinical evaluator of psoriasis performed an assessment of the overall severity of psoriasis and assigned a PGA-G score and category. 0=Clear, except for any residual discoloration (post-inflammatory hyperpigmentation and/or hypopigmentation) and 1=almost clear, the psoriasis is not entirely cleared and remaining plaques are light pink (not including post inflammatory hyperpigmentation), and/or have barely palpable elevation and/or have occasional fine scale. The PGA-G was a static assessment; i.e., without regard to a previous assessment.
Time frame: Baseline, Week 12
Percentage of Participants Achieving a PGA-G Response of Clear (0) or Almost Clear (1) and ≥2 Grade/Point Improvement From Baseline at Week 8
Clinical signs of plaque psoriasis (E, I and S) were scored separately according to a 5-point severity scale (0 to 4) to provide PGA subscores, which described the overall severity of each clinical sign. After scoring each of the PGA subscores, a clinical evaluator of psoriasis performed an assessment of the overall severity of psoriasis and assigned a PGA-G score and category. 0=Clear, except for any residual discoloration (post-inflammatory hyperpigmentation and/or hypopigmentation) and 1=almost clear, the psoriasis is not entirely cleared and remaining plaques are light pink (not including post inflammatory hyperpigmentation), and/or have barely palpable elevation and/or have occasional fine scale. The PGA-G was a static assessment; i.e., without regard to a previous assessment.
Time frame: Baseline, Week 8
Percent Change From Baseline to Week 12 in Psoriasis Area and Severity Index (PASI)
Combined assessment of lesion severity and area affected into single score. Body was divided into 4 regions: head, arms, trunk, legs. For each region, percent (%) area of skin involved was estimated: 0=0% to 6=90-100%. Severity was estimated by clinical signs: erythema, induration, scaling; scale: 0=none to 4=maximum. Final PASI = sum of severity parameters for each region\*area score\*weight of region (head: 0.1, arms: 0.2, body: 0.3, legs: 0.4); total possible score range: 0=no disease to 72=maximal disease. The maximum PASI score was \<72 since the PASI assessment excluded scalp, palms, finger nails, soles, and toe nails.
Time frame: Baseline, Week 12
Percent Change From Baseline to Week 8 in PASI
Combined assessment of lesion severity and area affected into single score. Body was divided into 4 regions: head, arms, trunk, legs. For each region, percent area of skin involved was estimated: 0=0% to 6=90-100%. Severity was estimated by clinical signs: erythema, induration, scaling; scale: 0=none to 4=maximum. Final PASI = sum of severity parameters for each region\*area score\*weight of region (head: 0.1, arms: 0.2, body: 0.3, legs: 0.4); total possible score range: 0=no disease to 72=maximal disease. The maximum PASI score was \<72 since the PASI assessment excluded scalp, palms, finger nails, soles, and toe nails.
Time frame: Baseline, Week 8
Percentage of Participants Achieving at Least a 75% Reduction in PASI Response (PASI75), Relative to Baseline at Week 12
Combined assessment of lesion severity and area affected into single score. Body was divided into 4 regions: head, arms, trunk, legs. For each region, percent area of skin involved was estimated: 0=0% to 6=90-100%. Severity was estimated by clinical signs: erythema, induration, scaling; scale: 0=none to 4=maximum. Final PASI = sum of severity parameters for each region\*area score\*weight of region (head: 0.1, arms: 0.2, body: 0.3, legs: 0.4); total possible score range: 0=no disease to 72=maximal disease. The maximum PASI score was \<72 since the PASI assessment excluded scalp, palms, finger nails, soles, and toe nails.
Time frame: Baseline, Week 12
Percentage of Participants Achieving PASI75, Relative to Baseline at Week 8
Combined assessment of lesion severity and area affected into single score. Body was divided into 4 regions: head, arms, trunk, legs. For each region, percent area of skin involved was estimated: 0=0% to 6=90-100%. Severity was estimated by clinical signs: erythema, induration, scaling; scale: 0=none to 4=maximum. Final PASI = sum of severity parameters for each region\*area score\*weight of region (head: 0.1, arms: 0.2, body: 0.3, legs: 0.4); total possible score range: 0=no disease to 72=maximal disease. The maximum PASI score was \<72 since the PASI assessment excluded scalp, palms, finger nails, soles, and toe nails.
Time frame: Baseline, Week 8
Percent Change From Baseline to Week 12 in Body Surface Area (BSA) Affected With Psoriasis
Assessment of BSA with psoriasis was performed separately for 4 body regions: head and neck, upper limbs, trunk (including axillae and groin), and lower limbs (including buttocks). The percent surface area with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant represents approximately 1% of the total BSA. The number of handprints of psoriatic skin in a body region can be used to determine the extent (%) to which a body regions is involved with psoriasis. BSA (%)=the sum of the BSAs of the 4 body regions. BSA assessment excluded head and neck, palms, finger nails, soles and toe nails.
Time frame: Baseline, Week 12
Percent Change From Baseline to Week 8 in BSA Affected With Psoriasis
Assessment of BSA with psoriasis was performed separately for 4 body regions: head and neck, upper limbs, trunk (including axillae and groin), and lower limbs (including buttocks). The percent surface area with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant represents approximately 1% of the total BSA. The number of handprints of psoriatic skin in a body region can be used to determine the extent (%) to which a body regions is involved with psoriasis. BSA (%)=the sum of the BSAs of the 4 body regions. BSA assessment excluded head and neck, palms, finger nails, soles and toe nails.
Time frame: Baseline, Week 8
Change From Baseline to Week 12 in Clinic-Based Itch Severity Item (ISI) Scores
The severity of itch (pruritus) due to psoriasis was assessed using the ISI. Participants were asked to assess their "worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "no itching" (0) and "worst possible itching" (10) at the ends. Participants completed the ISI assessments at the clinic (i.e., clinic-based).
Time frame: Baseline, Week 12
Change From Baseline to Week 8 in Clinic-Based ISI Scores
The severity of itch (pruritus) due to psoriasis was assessed using the ISI. Participants were asked to assess their "worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "no itching" (0) and "worst possible itching" (10) at the ends. Participants completed the ISI assessments at the clinic (i.e., clinic-based).
Time frame: Baseline, Week 8
Change From Baseline to Week 12 in the Dermatology Life Quality Index (DLQI) Total Score
DLQI is the dermatology-specific quality of life measure used for psoriatic population. The 10-item questionnaire assesses participant health-related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life.
Time frame: Baseline, Week 12
Change From Baseline to Week 8 in the DLQI Total Score
DLQI is the dermatology-specific quality of life measure used for psoriatic population. The 10-item questionnaire assesses participant health-related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life.
Time frame: Baseline, Week 8
Percentage of Participants Achieving a Patient's Global Assessment (PtGA) Response of Clear (0) or Almost Clear (1) and ≥2 Grade/Point Improvement From Baseline at Week 12 for Participants With a PtGA Score ≥2 at Baseline
The PtGA asks the participant to evaluate the overall cutaneous disease at that point in time on a single item, 5-point scale (0=clear; 1=almost clear; 2=mild; 3=moderate; 4=severe).
Time frame: Baseline, Week 12
Percentage of Participants Achieving a PtGA Response of Clear (0) or Almost Clear (1) and ≥2 Grade/Point Improvement From Baseline at Week 8 for Participants With a PtGA Score ≥2 at Baseline
The PtGA asks the participant to evaluate the overall cutaneous disease at that point in time on a single item, 5-point scale (0=clear; 1=almost clear; 2=mild; 3=moderate; 4=severe).
Time frame: Baseline, Week 8
Participants with mild (PGA-C score of 2), moderate (PGA-C score of 3), or severe (PGA-C score of 4) chronic plaque psoriasis were recruited for this study. The primary analysis population for this study included only the participants with mild and moderate disease.
| Milestone | Mild/Moderate: Tofacitinib 20 mg/Gram (mg/g) Twice Daily (BID) | Mild/Moderate: Tofacitinib 10 mg/g BID | Mild/Moderate: Placebo (Vehicle) BID | Mild/Moderate: Tofacitinib 20 mg/g Once Daily (QD) | Mild/Moderate: Tofacitinib 10 mg/g QD | Mild/Moderate: Placebo (Vehicle) QD | Severe: Tofacitinib 20 mg/g BID | Severe: Tofacitinib 10 mg/g BID | Severe: Placebo (Vehicle) BID | Severe: Tofacitinib 20 mg/g QD | Severe: Tofacitinib 10 mg/g QD | Severe: Placebo (Vehicle) QD |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 71 | 70 | 71 | 70 | 74 | 74 | 7 | 7 | 7 | 7 | 6 | 7 |
| Completed | 55 | 52 | 48 | 51 | 57 | 48 | 6 | 5 | 4 | 2 | 4 | 3 |
| Not completed | 16 | 18 | 23 | 19 | 17 | 26 | 1 | 2 | 3 | 5 | 2 | 4 |
| Withdrew: Protocol violation | 1 | 1 | 2 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Other | 2 | 3 | 2 | 2 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Non-compliance with study treatment | 2 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Death | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 6 | 3 | 3 | 3 | 3 | 5 | 0 | 0 | 0 | 1 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 | 4 | 2 | 0 | 3 | 0 | 0 | 0 | 1 | 0 | 1 |
| Withdrew: Lack of efficacy | 5 | 8 | 7 | 6 | 9 | 8 | 1 | 1 | 2 | 2 | 2 | 0 |
| Withdrew: Adverse event | 0 | 0 | 4 | 6 | 3 | 7 | 0 | 1 | 1 | 1 | 0 | 2 |
Clinical signs of plaque psoriasis (erythema \[E\], induration \[I\], and scaling \[S\]) were scored separately according to a 5-point severity scale (0 to 4) to provide PGA subscores, which described the overall severity of each clinical sign. The PGA-C was a static assessment; i.e., without regard to a previous assessment. The PGA subscores are then summed and averaged after which the total average was rounded to the nearest whole number to determine the PGA-C score and category. A higher score indicated a higher level of severity. 0 is equal to (=) cleared except for any residual discoloration and 1=almost clear, majority of lesions had individual scores for E+I+S that when summed, averaged, and rounded equaled 1.
| Percentage of Participants | Mild/Moderate: Tofacitinib 20 mg/g BID | Mild/Moderate: Tofacitinib 10 mg/g BID | Mild/Moderate: Placebo (Vehicle) BID | Mild/Moderate: Tofacitinib 20 mg/g QD | Mild/Moderate: Tofacitinib 10 mg/g QD | Mild/Moderate: Placebo (Vehicle) QD |
|---|---|---|---|---|---|---|
| Percentage of Participants Achieving a PGA-C Response of Clear (0) or Almost Clear (1) and Greater Than or Equal to (≥) 2 Grade/Point Improvement From Baseline at Week 12 | 21.1 | 12.9 | 16.9 | 20.0 | 21.6 | 17.6 |
Clinical signs of plaque psoriasis (E, I, and S) were scored separately according to a 5-point severity scale (0 to 4) to provide PGA subscores, which described the overall severity of each clinical sign. The PGA-C was a static assessment; i.e., without regard to a previous assessment. The PGA subscores are then summed and averaged after which the total average was rounded to the nearest whole number to determine the PGA-C score and category. A higher score indicated a higher level of severity. 0 is equal to (=) cleared except for any residual discoloration and 1=almost clear, majority of lesions had individual scores for E+I+S that when summed, averaged, and rounded equaled 1.
| Percentage of Participants | Mild/Moderate: Tofacitinib 20 mg/g BID | Mild/Moderate: Tofacitinib 10 mg/g BID | Mild/Moderate: Placebo (Vehicle) BID | Mild/Moderate: Tofacitinib 20 mg/g QD | Mild/Moderate: Tofacitinib 10 mg/g QD | Mild/Moderate: Placebo (Vehicle) QD |
|---|---|---|---|---|---|---|
| Percentage of Participants Achieving a PGA-C Response of Clear (0) or Almost Clear (1) and ≥2 Grade/Point Improvement From Baseline at Week 8 | 22.5 | 10.0 | 11.3 | 18.6 | 14.9 | 8.1 |
Clinical signs of plaque psoriasis (E, I, and S) were scored separately according to a 5-point severity scale (0 to 4) to provide PGA subscores, which described the overall severity of each clinical sign. The PGA-C was a static assessment; i.e., without regard to a previous assessment. The PGA subscores are then summed and averaged after which the total average was rounded to the nearest whole number to determine the PGA-C score and category. A higher score indicated a higher level of severity. 0 is equal to (=) cleared except for any residual discoloration and 1=almost clear, majority of lesions had individual scores for E+I+S that when summed, averaged, and rounded equaled 1.
| Percentage of Participants | Mild/Moderate: Tofacitinib 20 mg/g BID | Mild/Moderate: Tofacitinib 10 mg/g BID | Mild/Moderate: Placebo (Vehicle) BID | Mild/Moderate: Tofacitinib 20 mg/g QD | Mild/Moderate: Tofacitinib 10 mg/g QD | Mild/Moderate: Placebo (Vehicle) QD |
|---|---|---|---|---|---|---|
| Percentage of Participants Achieving a PGA-C Response of Clear (0) or Almost Clear (1) at Week 12 | 33.8 | 25.7 | 23.9 | 27.1 | 29.7 | 23.0 |
Clinical signs of plaque psoriasis (E, I, and S) were scored separately according to a 5-point severity scale (0 to 4) to provide PGA subscores, which described the overall severity of each clinical sign. The PGA-C was a static assessment; i.e., without regard to a previous assessment. The PGA subscores are then summed and averaged after which the total average was rounded to the nearest whole number to determine the PGA-C score and category. A higher score indicated a higher level of severity. 0 is equal to (=) cleared except for any residual discoloration and 1=almost clear, majority of lesions had individual scores for E+I+S that when summed, averaged, and rounded equaled 1.
| Percentage of Participants | Mild/Moderate: Tofacitinib 20 mg/g BID | Mild/Moderate: Tofacitinib 10 mg/g BID | Mild/Moderate: Placebo (Vehicle) BID | Mild/Moderate: Tofacitinib 20 mg/g QD | Mild/Moderate: Tofacitinib 10 mg/g QD | Mild/Moderate: Placebo (Vehicle) QD |
|---|---|---|---|---|---|---|
| Percentage of Participants Achieving a PGA-C Response of Clear (0) or Almost Clear (1) at Week 8 | 36.6 | 20.0 | 22.5 | 32.9 | 21.6 | 12.2 |
Clinical signs of plaque psoriasis (E, I and S) were scored separately according to a 5-point severity scale (0 to 4) to provide PGA subscores, which described the overall severity of each clinical sign. After scoring each of the PGA subscores, a clinical evaluator of psoriasis performed an assessment of the overall severity of psoriasis and assigned a PGA-G score and category. 0=Clear, except for any residual discoloration (post-inflammatory hyperpigmentation and/or hypopigmentation) and 1=almost clear, the psoriasis is not entirely cleared and remaining plaques are light pink (not including post inflammatory hyperpigmentation), and/or have barely palpable elevation and/or have occasional fine scale. The PGA-G was a static assessment; i.e., without regard to a previous assessment.
| Percentage of Participants | Mild/Moderate: Tofacitinib 20 mg/g BID | Mild/Moderate: Tofacitinib 10 mg/g BID | Mild/Moderate: Placebo (Vehicle) BID | Mild/Moderate: Tofacitinib 20 mg/g QD | Mild/Moderate: Tofacitinib 10 mg/g QD | Mild/Moderate: Placebo (Vehicle) QD |
|---|---|---|---|---|---|---|
| Percentage of Participants Achieving a Gestalt Physician's Global Assessment (PGA-G) Response of Clear (0) or Almost Clear (1) and ≥2 Grade/Point Improvement From Baseline at Week 12 | 18.3 | 11.4 | 14.1 | 15.7 | 18.9 | 12.2 |
Clinical signs of plaque psoriasis (E, I and S) were scored separately according to a 5-point severity scale (0 to 4) to provide PGA subscores, which described the overall severity of each clinical sign. After scoring each of the PGA subscores, a clinical evaluator of psoriasis performed an assessment of the overall severity of psoriasis and assigned a PGA-G score and category. 0=Clear, except for any residual discoloration (post-inflammatory hyperpigmentation and/or hypopigmentation) and 1=almost clear, the psoriasis is not entirely cleared and remaining plaques are light pink (not including post inflammatory hyperpigmentation), and/or have barely palpable elevation and/or have occasional fine scale. The PGA-G was a static assessment; i.e., without regard to a previous assessment.
| Percentage of Participants | Mild/Moderate: Tofacitinib 20 mg/g BID | Mild/Moderate: Tofacitinib 10 mg/g BID | Mild/Moderate: Placebo (Vehicle) BID | Mild/Moderate: Tofacitinib 20 mg/g QD | Mild/Moderate: Tofacitinib 10 mg/g QD | Mild/Moderate: Placebo (Vehicle) QD |
|---|---|---|---|---|---|---|
| Percentage of Participants Achieving a PGA-G Response of Clear (0) or Almost Clear (1) and ≥2 Grade/Point Improvement From Baseline at Week 8 | 21.1 | 7.1 | 11.3 | 15.7 | 9.5 | 4.1 |
Combined assessment of lesion severity and area affected into single score. Body was divided into 4 regions: head, arms, trunk, legs. For each region, percent (%) area of skin involved was estimated: 0=0% to 6=90-100%. Severity was estimated by clinical signs: erythema, induration, scaling; scale: 0=none to 4=maximum. Final PASI = sum of severity parameters for each region\*area score\*weight of region (head: 0.1, arms: 0.2, body: 0.3, legs: 0.4); total possible score range: 0=no disease to 72=maximal disease. The maximum PASI score was \<72 since the PASI assessment excluded scalp, palms, finger nails, soles, and toe nails.
| Percent Change from Baseline | Mild/Moderate: Tofacitinib 20 mg/g BID | Mild/Moderate: Tofacitinib 10 mg/g BID | Mild/Moderate: Placebo (Vehicle) BID | Mild/Moderate: Tofacitinib 20 mg/g QD | Mild/Moderate: Tofacitinib 10 mg/g QD | Mild/Moderate: Placebo (Vehicle) QD |
|---|---|---|---|---|---|---|
| Percent Change From Baseline to Week 12 in Psoriasis Area and Severity Index (PASI) | -36.6 ± 40.88 | -35.7 ± 43.78 | -32.0 ± 49.47 | -38.6 ± 36.37 | -31.4 ± 42.36 | -30.0 ± 38.68 |
Combined assessment of lesion severity and area affected into single score. Body was divided into 4 regions: head, arms, trunk, legs. For each region, percent area of skin involved was estimated: 0=0% to 6=90-100%. Severity was estimated by clinical signs: erythema, induration, scaling; scale: 0=none to 4=maximum. Final PASI = sum of severity parameters for each region\*area score\*weight of region (head: 0.1, arms: 0.2, body: 0.3, legs: 0.4); total possible score range: 0=no disease to 72=maximal disease. The maximum PASI score was \<72 since the PASI assessment excluded scalp, palms, finger nails, soles, and toe nails.
| Percent Change from Baseline | Mild/Moderate: Tofacitinib 20 mg/g BID | Mild/Moderate: Tofacitinib 10 mg/g BID | Mild/Moderate: Placebo (Vehicle) BID | Mild/Moderate: Tofacitinib 20 mg/g QD | Mild/Moderate: Tofacitinib 10 mg/g QD | Mild/Moderate: Placebo (Vehicle) QD |
|---|---|---|---|---|---|---|
| Percent Change From Baseline to Week 8 in PASI | -36.7 ± 36.01 | -29.1 ± 40.86 | -28.8 ± 37.06 | -36.5 ± 33.87 | -29.0 ± 29.47 | -27.1 ± 32.93 |
Combined assessment of lesion severity and area affected into single score. Body was divided into 4 regions: head, arms, trunk, legs. For each region, percent area of skin involved was estimated: 0=0% to 6=90-100%. Severity was estimated by clinical signs: erythema, induration, scaling; scale: 0=none to 4=maximum. Final PASI = sum of severity parameters for each region\*area score\*weight of region (head: 0.1, arms: 0.2, body: 0.3, legs: 0.4); total possible score range: 0=no disease to 72=maximal disease. The maximum PASI score was \<72 since the PASI assessment excluded scalp, palms, finger nails, soles, and toe nails.
| Percentage of Participants | Mild/Moderate: Tofacitinib 20 mg/g BID | Mild/Moderate: Tofacitinib 10 mg/g BID | Mild/Moderate: Placebo (Vehicle) BID | Mild/Moderate: Tofacitinib 20 mg/g QD | Mild/Moderate: Tofacitinib 10 mg/g QD | Mild/Moderate: Placebo (Vehicle) QD |
|---|---|---|---|---|---|---|
| Percentage of Participants Achieving at Least a 75% Reduction in PASI Response (PASI75), Relative to Baseline at Week 12 | 16.9 | 12.9 | 12.7 | 15.7 | 10.8 | 6.8 |
Combined assessment of lesion severity and area affected into single score. Body was divided into 4 regions: head, arms, trunk, legs. For each region, percent area of skin involved was estimated: 0=0% to 6=90-100%. Severity was estimated by clinical signs: erythema, induration, scaling; scale: 0=none to 4=maximum. Final PASI = sum of severity parameters for each region\*area score\*weight of region (head: 0.1, arms: 0.2, body: 0.3, legs: 0.4); total possible score range: 0=no disease to 72=maximal disease. The maximum PASI score was \<72 since the PASI assessment excluded scalp, palms, finger nails, soles, and toe nails.
| Percentage of Participants | Mild/Moderate: Tofacitinib 20 mg/g BID | Mild/Moderate: Tofacitinib 10 mg/g BID | Mild/Moderate: Placebo (Vehicle) BID | Mild/Moderate: Tofacitinib 20 mg/g QD | Mild/Moderate: Tofacitinib 10 mg/g QD | Mild/Moderate: Placebo (Vehicle) QD |
|---|---|---|---|---|---|---|
| Percentage of Participants Achieving PASI75, Relative to Baseline at Week 8 | 14.1 | 8.6 | 7.0 | 15.7 | 6.8 | 6.8 |
Assessment of BSA with psoriasis was performed separately for 4 body regions: head and neck, upper limbs, trunk (including axillae and groin), and lower limbs (including buttocks). The percent surface area with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant represents approximately 1% of the total BSA. The number of handprints of psoriatic skin in a body region can be used to determine the extent (%) to which a body regions is involved with psoriasis. BSA (%)=the sum of the BSAs of the 4 body regions. BSA assessment excluded head and neck, palms, finger nails, soles and toe nails.
| Percent Change from Baseline | Mild/Moderate: Tofacitinib 20 mg/g BID | Mild/Moderate: Tofacitinib 10 mg/g BID | Mild/Moderate: Placebo (Vehicle) BID | Mild/Moderate: Tofacitinib 20 mg/g QD | Mild/Moderate: Tofacitinib 10 mg/g QD | Mild/Moderate: Placebo (Vehicle) QD |
|---|---|---|---|---|---|---|
| Percent Change From Baseline to Week 12 in Body Surface Area (BSA) Affected With Psoriasis | -32.8 ± 40.92 | -27.5 ± 36.40 | -27.7 ± 43.43 | -24.6 ± 36.29 | -15.6 ± 36.63 | -11.2 ± 56.38 |
Assessment of BSA with psoriasis was performed separately for 4 body regions: head and neck, upper limbs, trunk (including axillae and groin), and lower limbs (including buttocks). The percent surface area with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant represents approximately 1% of the total BSA. The number of handprints of psoriatic skin in a body region can be used to determine the extent (%) to which a body regions is involved with psoriasis. BSA (%)=the sum of the BSAs of the 4 body regions. BSA assessment excluded head and neck, palms, finger nails, soles and toe nails.
| Percent Change from Baseline | Mild/Moderate: Tofacitinib 20 mg/g BID | Mild/Moderate: Tofacitinib 10 mg/g BID | Mild/Moderate: Placebo (Vehicle) BID | Mild/Moderate: Tofacitinib 20 mg/g QD | Mild/Moderate: Tofacitinib 10 mg/g QD | Mild/Moderate: Placebo (Vehicle) QD |
|---|---|---|---|---|---|---|
| Percent Change From Baseline to Week 8 in BSA Affected With Psoriasis | -25.4 ± 44.75 | -22.5 ± 35.87 | -20.5 ± 34.90 | -17.8 ± 28.59 | -9.0 ± 30.08 | -11.7 ± 38.29 |
The severity of itch (pruritus) due to psoriasis was assessed using the ISI. Participants were asked to assess their "worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "no itching" (0) and "worst possible itching" (10) at the ends. Participants completed the ISI assessments at the clinic (i.e., clinic-based).
| Score on a Scale | Mild/Moderate: Tofacitinib 20 mg/g BID | Mild/Moderate: Tofacitinib 10 mg/g BID | Mild/Moderate: Placebo (Vehicle) BID | Mild/Moderate: Tofacitinib 20 mg/g QD | Mild/Moderate: Tofacitinib 10 mg/g QD | Mild/Moderate: Placebo (Vehicle) QD |
|---|---|---|---|---|---|---|
| Change From Baseline to Week 12 in Clinic-Based Itch Severity Item (ISI) Scores | -2.88 ± 3.140 | -2.89 ± 3.320 | -1.73 ± 2.460 | -2.38 ± 3.182 | -1.94 ± 3.151 | -1.50 ± 2.961 |
The severity of itch (pruritus) due to psoriasis was assessed using the ISI. Participants were asked to assess their "worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "no itching" (0) and "worst possible itching" (10) at the ends. Participants completed the ISI assessments at the clinic (i.e., clinic-based).
| Score on a Scale | Mild/Moderate: Tofacitinib 20 mg/g BID | Mild/Moderate: Tofacitinib 10 mg/g BID | Mild/Moderate: Placebo (Vehicle) BID | Mild/Moderate: Tofacitinib 20 mg/g QD | Mild/Moderate: Tofacitinib 10 mg/g QD | Mild/Moderate: Placebo (Vehicle) QD |
|---|---|---|---|---|---|---|
| Change From Baseline to Week 8 in Clinic-Based ISI Scores | -3.07 ± 2.971 | -2.38 ± 2.984 | -1.45 ± 2.847 | -2.49 ± 2.769 | -1.91 ± 3.166 | -1.34 ± 3.285 |
DLQI is the dermatology-specific quality of life measure used for psoriatic population. The 10-item questionnaire assesses participant health-related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life.
| Score on a Scale | Mild/Moderate: Tofacitinib 20 mg/g BID | Mild/Moderate: Tofacitinib 10 mg/g BID | Mild/Moderate: Placebo (Vehicle) BID | Mild/Moderate: Tofacitinib 20 mg/g QD | Mild/Moderate: Tofacitinib 10 mg/g QD | Mild/Moderate: Placebo (Vehicle) QD |
|---|---|---|---|---|---|---|
| Change From Baseline to Week 12 in the Dermatology Life Quality Index (DLQI) Total Score | -4.6 ± 5.55 | -3.2 ± 5.32 | -2.6 ± 5.45 | -5.6 ± 7.04 | -3.3 ± 5.97 | -2.3 ± 6.34 |
DLQI is the dermatology-specific quality of life measure used for psoriatic population. The 10-item questionnaire assesses participant health-related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life.
| Score on a Scale | Mild/Moderate: Tofacitinib 20 mg/g BID | Mild/Moderate: Tofacitinib 10 mg/g BID | Mild/Moderate: Placebo (Vehicle) BID | Mild/Moderate: Tofacitinib 20 mg/g QD | Mild/Moderate: Tofacitinib 10 mg/g QD | Mild/Moderate: Placebo (Vehicle) QD |
|---|---|---|---|---|---|---|
| Change From Baseline to Week 8 in the DLQI Total Score | -4.6 ± 5.16 | -2.6 ± 4.98 | -2.8 ± 4.01 | -5.0 ± 5.85 | -2.7 ± 4.79 | -2.2 ± 5.63 |
The PtGA asks the participant to evaluate the overall cutaneous disease at that point in time on a single item, 5-point scale (0=clear; 1=almost clear; 2=mild; 3=moderate; 4=severe).
| Percentage of Participants | Mild/Moderate: Tofacitinib 20 mg/g BID | Mild/Moderate: Tofacitinib 10 mg/g BID | Mild/Moderate: Placebo (Vehicle) BID | Mild/Moderate: Tofacitinib 20 mg/g QD | Mild/Moderate: Tofacitinib 10 mg/g QD | Mild/Moderate: Placebo (Vehicle) QD |
|---|---|---|---|---|---|---|
| Percentage of Participants Achieving a Patient's Global Assessment (PtGA) Response of Clear (0) or Almost Clear (1) and ≥2 Grade/Point Improvement From Baseline at Week 12 for Participants With a PtGA Score ≥2 at Baseline | 8.8 | 17.5 | 7.3 | 13.2 | 14.5 | 7.7 |
The PtGA asks the participant to evaluate the overall cutaneous disease at that point in time on a single item, 5-point scale (0=clear; 1=almost clear; 2=mild; 3=moderate; 4=severe).
| Percentage of Participants | Mild/Moderate: Tofacitinib 20 mg/g BID | Mild/Moderate: Tofacitinib 10 mg/g BID | Mild/Moderate: Placebo (Vehicle) BID | Mild/Moderate: Tofacitinib 20 mg/g QD | Mild/Moderate: Tofacitinib 10 mg/g QD | Mild/Moderate: Placebo (Vehicle) QD |
|---|---|---|---|---|---|---|
| Percentage of Participants Achieving a PtGA Response of Clear (0) or Almost Clear (1) and ≥2 Grade/Point Improvement From Baseline at Week 8 for Participants With a PtGA Score ≥2 at Baseline | 5.0 | 6.3 | 10.9 | 10.0 | 6.0 | 1.7 |
Collected over SAEs were assessed from informed consent through and including 28 calendar days after last administration of study treatment. Non-SAEs were recorded from time of first dose of study treatment through last participant visit.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Mild/Moderate: Tofacitinib 20 mg/g BID | — | 0/71 (0%) | 30/71 (42.3%) |
| Mild/Moderate: Tofacitinib 10 mg/g BID | — | 5/70 (7.1%) | 29/70 (41.4%) |
| Mild/Moderate: Placebo (Vehicle) BID | — | 2/71 (2.8%) | 27/71 (38%) |
| Mild/Moderate: Tofacitinib 20 mg/g QD | — | 0/70 (0%) | 34/70 (48.6%) |
| Mild/Moderate: Tofacitinib 10 mg/g QD | — | 2/74 (2.7%) | 28/74 (37.8%) |
| Mild/Moderate: Placebo (Vehicle) QD | — | 1/74 (1.4%) | 40/74 (54.1%) |
| Severe: Tofacitinib 20 mg/g BID | — | 0/7 (0%) | 2/7 (28.6%) |
| Severe: Tofacitinib 10 mg/g BID | — | 0/7 (0%) | 4/7 (57.1%) |
| Severe: Placebo (Vehicle) BID | — | 0/7 (0%) | 4/7 (57.1%) |
| Severe: Tofacitinib 20 mg/g QD | — | 0/7 (0%) | 3/7 (42.9%) |
| Severe: Tofacitinib 10 mg/g QD | — | 0/6 (0%) | 2/6 (33.3%) |
| Severe: Placebo (Vehicle) QD | — | 1/7 (14.3%) | 2/7 (28.6%) |
| Event | Mild/Moderate: Tofacitinib 20 mg/g BID | Mild/Moderate: Tofacitinib 10 mg/g BID | Mild/Moderate: Placebo (Vehicle) BID | Mild/Moderate: Tofacitinib 20 mg/g QD | Mild/Moderate: Tofacitinib 10 mg/g QD | Mild/Moderate: Placebo (Vehicle) QD | Severe: Tofacitinib 20 mg/g BID | Severe: Tofacitinib 10 mg/g BID | Severe: Placebo (Vehicle) BID | Severe: Tofacitinib 20 mg/g QD | Severe: Tofacitinib 10 mg/g QD | Severe: Placebo (Vehicle) QD |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Transient ischaemic attackNervous system disorders | 0/71 | 0/70 | 0/71 | 0/70 | 0/74 | 0/74 | 0/7 | 0/7 | 0/7 | 0/7 | 0/6 | 1/7 |
| Cardiac failure congestiveCardiac disorders | 0/71 | 1/70 | 0/71 | 0/70 | 0/74 | 0/74 | 0/7 | 0/7 | 0/7 | 0/7 | 0/6 | 0/7 |
| Myocardial infarctionCardiac disorders | 0/71 | 1/70 | 0/71 | 0/70 | 0/74 | 0/74 | 0/7 | 0/7 | 0/7 | 0/7 | 0/6 | 0/7 |
| Non-cardiac chest painGeneral disorders | 0/71 | 1/70 | 0/71 | 0/70 | 0/74 | 0/74 | 0/7 | 0/7 | 0/7 | 0/7 | 0/6 | 0/7 |
| Abdominal wound dehiscenceInjury, poisoning and procedural complications | 0/71 | 1/70 | 0/71 | 0/70 | 0/74 | 0/74 | 0/7 | 0/7 | 0/7 | 0/7 | 0/6 | 0/7 |
| Diabetes mellitusMetabolism and nutrition disorders | 0/71 | 1/70 | 0/71 | 0/70 | 0/74 | 0/74 | 0/7 | 0/7 | 0/7 | 0/7 | 0/6 | 0/7 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/71 | 0/70 | 1/71 | 0/70 | 0/74 | 0/74 | 0/7 | 0/7 | 0/7 | 0/7 | 0/6 | 0/7 |
| Psoriatic arthropathyMusculoskeletal and connective tissue disorders | 0/71 | 0/70 | 1/71 | 0/70 | 0/74 | 0/74 | 0/7 | 0/7 | 0/7 | 0/7 | 0/6 | 0/7 |
| ArrhythmiaCardiac disorders | 0/71 | 0/70 | 0/71 | 0/70 | 1/74 | 0/74 | 0/7 | 0/7 | 0/7 | 0/7 | 0/6 | 0/7 |
| Atrial fibrillationCardiac disorders | 0/71 | 0/70 | 0/71 | 0/70 | 0/74 | 1/74 | 0/7 | 0/7 | 0/7 | 0/7 | 0/6 | 0/7 |
| Event | Mild/Moderate: Tofacitinib 20 mg/g BID | Mild/Moderate: Tofacitinib 10 mg/g BID | Mild/Moderate: Placebo (Vehicle) BID | Mild/Moderate: Tofacitinib 20 mg/g QD | Mild/Moderate: Tofacitinib 10 mg/g QD | Mild/Moderate: Placebo (Vehicle) QD | Severe: Tofacitinib 20 mg/g BID | Severe: Tofacitinib 10 mg/g BID | Severe: Placebo (Vehicle) BID | Severe: Tofacitinib 20 mg/g QD | Severe: Tofacitinib 10 mg/g QD | Severe: Placebo (Vehicle) QD |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PsoriasisSkin and subcutaneous tissue disorders | 1/71 | 1/70 | 0/71 | 7/70 | 6/74 | 6/74 | 1/7 | 0/7 | 0/7 | 2/7 | 0/6 | 1/7 |
| Ear infectionInfections and infestations | 1/71 | 0/70 | 0/71 | 0/70 | 0/74 | 0/74 | 0/7 | 0/7 | 0/7 | 0/7 | 1/6 | 0/7 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 0/71 | 0/70 | 0/71 | 1/70 | 0/74 | 1/74 | 0/7 | 0/7 | 0/7 | 0/7 | 1/6 | 0/7 |
| NasopharyngitisInfections and infestations | 3/71 | 2/70 | 1/71 | 5/70 | 7/74 | 11/74 | 0/7 | 1/7 | 0/7 | 0/7 | 0/6 | 0/7 |
| NauseaGastrointestinal disorders | 2/71 | 1/70 | 1/71 | 1/70 | 3/74 | 0/74 | 1/7 | 0/7 | 0/7 | 0/7 | 0/6 | 0/7 |
| Chest painGeneral disorders | 0/71 | 0/70 | 1/71 | 0/70 | 0/74 | 0/74 | 0/7 | 0/7 | 1/7 | 0/7 | 0/6 | 0/7 |
| FatigueGeneral disorders | 0/71 | 0/70 | 1/71 | 0/70 | 0/74 | 0/74 | 0/7 | 0/7 | 1/7 | 0/7 | 0/6 | 0/7 |
| Oedema peripheralGeneral disorders | 0/71 | 0/70 | 0/71 | 1/70 | 0/74 | 0/74 | 0/7 | 1/7 | 0/7 | 0/7 | 0/6 | 0/7 |
| BronchitisInfections and infestations | 2/71 | 1/70 | 0/71 | 1/70 | 1/74 | 1/74 | 1/7 | 0/7 | 1/7 | 0/7 | 0/6 | 0/7 |
| Upper respiratory tract infectionInfections and infestations | 2/71 | 10/70 | 6/71 | 2/70 | 0/74 | 1/74 | 1/7 | 0/7 | 0/7 | 0/7 | 0/6 | 0/7 |
Full Analysis Set (FAS) - included all participants who were randomized to the study, received at least one dose of the randomized investigational drug (tofacitinib or vehicle), and were in a baseline PGA-C category of mild (2), moderate (3) or severe (4).
| Age, Customized(Participants) | Mild/Moderate: Tofacitinib 20 mg/g BID | Mild/Moderate: Tofacitinib 10 mg/g BID | Mild/Moderate: Placebo (Vehicle) BID | Mild/Moderate: Tofacitinib 20 mg/g QD | Mild/Moderate: Tofacitinib 10 mg/g QD | Mild/Moderate: Placebo (Vehicle) QD | Severe: Tofacitinib 20 mg/g BID | Severe: Tofacitinib 10 mg/g BID | Severe: Placebo (Vehicle) BID | Severe: Tofacitinib 20 mg/g QD | Severe: Tofacitinib 10 mg/g QD | Severe: Placebo (Vehicle) QD | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| < 18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 18-44 years | 30 | 23 | 25 | 21 | 30 | 25 | 2 | 0 | 1 | 3 | 3 | 2 | 165 |
| 45-64 years | 28 | 34 | 34 | 38 | 35 | 39 | 4 | 6 | 4 | 2 | 2 | 2 | 228 |
| >= 65 years | 13 | 13 | 12 | 11 | 9 | 10 | 1 | 1 | 2 | 2 | 1 | 3 | 78 |
| Sex: Female, Male(Participants) | Mild/Moderate: Tofacitinib 20 mg/g BID | Mild/Moderate: Tofacitinib 10 mg/g BID | Mild/Moderate: Placebo (Vehicle) BID | Mild/Moderate: Tofacitinib 20 mg/g QD | Mild/Moderate: Tofacitinib 10 mg/g QD | Mild/Moderate: Placebo (Vehicle) QD | Severe: Tofacitinib 20 mg/g BID | Severe: Tofacitinib 10 mg/g BID | Severe: Placebo (Vehicle) BID | Severe: Tofacitinib 20 mg/g QD | Severe: Tofacitinib 10 mg/g QD | Severe: Placebo (Vehicle) QD | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 28 | 23 | 30 | 33 | 24 | 32 | 1 | 3 | 1 | 1 | 0 | 0 | 176 |
| Male | 43 | 47 | 41 | 37 | 50 | 42 | 6 | 4 | 6 | 6 | 6 | 7 | 295 |
The record gives a start of May 2013, a primary completion of Sep 2014 and a completion of Sep 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2015, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tofacitinib